步長製藥股票討論區

Shandong Buchang Pharmaceuticals' share price and EPS decline over the past three years hint at ongoing challenges. The company's underperformance compared to the broader market over the past year may suggest unresolved issues. Investors should consider market conditions and other key factors.

Shandong Buchang Pharmaceuticals' low P/S ratio may reflect expectations of continued disappointing revenue performance. The company's declining revenue and predicted industry growth could challenge its current P/S ratio, potentially disappointing shareholders. Current investor sentiment and future expectations do not seem to justify a higher P/S ratio for the company.

The recent sell-off could be an opportunity, but it's recommended to check the fundamental data for signs of a long-term growth trend. There are also 2 warning signs for the company that should be considered.